







HORIBAJOBIN YVON





Contact

Prof. Francesco Michelotti (Coordinator) Università di Roma "La Sapienza" Dipartimento di Scienza di Base ed Applicate per l'Ingegneria Via Antonio Scarpa, 16 00161 Roma Italy

 Tel:
 +39 06 49 91 65 62

 Fax:
 +39 06 44 24 01 83

 E-mail:
 francesco.michelotti@uniroma1.it

Website: www.biloba-project.eu

An European

multidisciplinary Collaborative Project funded by the European Commission under the Theme 3 "Information and Communication Technologies" of the Seventh Framework Programme Call: FP7-ICT-2011-8 Contract Number: 318035

A consortium of 9 partners from 4 EU member states:

- 4 universities
- 1 research institute 4 industrial partners

fields ranging from physics and chemistry to biology and medicine.

Budget: €4.73 million including €3.60 million from the European Commission

Duration 36 months (Oct 2012- Sept 2015)



Bloch electromagnetic surface wave biosensors for early cancer diagnosis





Objective

BILOBA aims to develop and pre-clinically validate a multi-functional point-of-care platform capable of performing real-time cancer biomarker detection in a tandem configuration. The unique properties of Bloch surface waves (BSW) sustained at the surface of 1D photonic crystals (1DPC) will be advantageously implemented. Therein, a surface wave without absorption is excited, giving rise to an enormous increase of sensitivity with respect to surface perturbations. Furthermore, fluorescence enhancement due to near field effects will be exploited. By engineering the BSW dispersion both detection schemes will be combined.

Expected impact

- The BILOBA platform represents a breakthrough in ultra-sensitive photonic systems for non invasive and point of care early diagnosis of cancer.
- BILOBA can potentially outperform conventional approaches and set a new standard for early recognition of malignancies.
- The increased performance of the BSW biochips will have a tremendous impact on the medical community, allowing cancer diagnosis at a very early stage with consequent increase of quality of life for the patients, increase of lifetime, and decrease of treatment costs.

Approach

1. BSW Biochips

Disposable biochips, where a dielectric 1DPC is integrated on top of a plastic slide with micro-optical elements, are the core of the sensing platform.

2. Reading device

An optical system capable of detecting fluorescent labels as well as performing labelfree analysis will be designed and implemented hand-inhand with the BSW biochips

development. All components will be integrated into one platform comprising appropriate software and interfaces

3. Bioreceptors


High molecular selectivity will be reached by immobilizing on the biochips surface specific probe bioreceptors. that will selectively catch the target cancer biomarkers to be detected.

4. Microfluidics

The development of a sophisticated, robust fluidic system to ensure a high signal to noise ratio even in the case of lowest analyte concentrations accompanies the work.

5. Validation

The results will be applied to early cancer biomarker analysis by validating the project's results in preclinical tests.



Application

The target application is the detection of Angiopoietin-1, Angiopoietin-2 and Vascular Endothelial Growth Factor (VEGF-A) with these proteins being indicative of angiogenesis associated to human cancer progression.

Such markers have already been studied by some of the proponents both from the medical point of view and from the sensing application point of view. In particular at a medical level, the proponents have set up preclinical and clinical strategies to correlate disease progression and disease-free survival with molecular and biological markers of angiogenesis.

Consortium

- Università di Roma "La Sapienza", Department of Basic and Applied Sciences for Engineering - Italy
- Politecnico di Torino, Department of Applied Sciences and Technology Italy
- Fraunhofer Institute for Applied Optics and Precision Engineering IOF (Jena) and Institute for Material and Beam Technology IWS (Dresden) – Germany
- Imperial College of London, Department of Materials United Kingdom
- Università di Torino, Department of Oncology Italy
- LABOR Srl Italy
- Biotray SAS France
- HORIBA Jobin Yvon SAS France
- KDS Radeberg GmbH Germany